Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 29, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

GlobeNewsWire • Jan 29, 2026

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.

Seeking Alpha • Jan 30, 2026

These Are The 5 Best Stocks To Buy Now Or Watch

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.

Investors Business Daily • Jan 26, 2026

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 14,351 million in 2025. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world.

GlobeNewsWire • Jan 21, 2026

Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside

On Friday, Genmab A/S (NASDAQ: GMAB) released topline results from the Phase 3 EPCORE DLBCL-1 trial of epcoritamab for diffuse large B-cell lymphoma (DLBCL).

Benzinga • Jan 20, 2026

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to improve the survival rate in patients in a late-stage study.

Reuters • Jan 16, 2026

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additionally, improvements were observed in the complete response rate, duration of response, and time to next treatment.

Business Wire • Jan 16, 2026

Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

Genmab: AI Partnership And Clinical Data Fuel Growth

Genmab is transitioning from a royalty-driven licensor to an innovation powerhouse with a robust, proprietary pipeline. GMAB delivered 21% revenue growth and 52% operating profit growth, supported by $3.4B in cash and strong operating leverage. Epkinly and Rina-S, with positive clinical data and full or majority ownership, underpin GMAB's multi-billion dollar peak sales potential.

Seeking Alpha • Jan 10, 2026

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

COPENHAGEN, Denmark--(BUSINESS WIRE)-- #AI--Genmab has partnered with Anthropic to advance its research and development (R&D) processes through the adoption of agentic AI capabilities.

Business Wire • Jan 7, 2026